RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Checkmate Pharmaceuticals Stock

Checkmate Pharmaceuticals Equity 2024

Checkmate Pharmaceuticals Equity

69.46 M USD

Ticker

CMPI

ISIN

US1628181083

WKN

A2QAMD

In 2024, Checkmate Pharmaceuticals's equity was 69.46 M USD, a 0% increase from the 0 USD equity in the previous year.

Checkmate Pharmaceuticals Aktienanalyse

What does Checkmate Pharmaceuticals do?

Checkmate Pharmaceuticals Inc is a biopharmaceutical company based in Cambridge, Massachusetts. It was founded in 2015 and specializes in the research and development of immuno-oncology therapies. The company has an innovative business model aimed at improving the immune response against cancer. It utilizes the natural ability of the immune system to recognize and eliminate cancer cells. Immuno-oncology is a major trend in cancer therapy today, with the goal of harnessing the body's own immune system to fight cancer cells. Checkmate Pharmaceuticals focuses on the development of unique first-in-class immunotherapeutics. The company collaborates closely with leading academic institutions and international organizations to maximize the potential of its technology and achieve the best results. The business of Checkmate Pharmaceuticals can be divided into three areas, from the Checkmate platform technology, for which multiple patents have been filed, to the two products: CMP-001 (classified as Breakthrough Therapy) and CMP-003. The Checkmate platform technology is based on stimulating immune responses through the ligation of oligonucleotides, which in turn is intended to promote the recognition and elimination of cancer cells. This method aims to safely and effectively harness the benefits of immunotherapy and successfully control the potential hazards of the immune system. CMP-001 is an immunotherapeutic currently in phase 2a clinical development. It is a combination of an adjuvant called STING agonists (also known as Sting-Signalling agonist) and a toll-like receptor-ligand of nucleotide (TLR-9), which help stimulate the body's immune system and trigger an immune response against cancer cells. CMP-001 has been granted 'Breakthrough Therapy' status by the US FDA, meaning that the drug offers a significant advancement in the treatment of patients with serious or life-threatening diseases compared to currently available therapies. CMP-003 is another development by Checkmate Pharmaceuticals, aiming to regulate excessive immune response. Along with STING, antibodies against poxviruses have been shown to activate the immune system and enable effective tumor therapy. One of the main target populations for Checkmate Pharmaceuticals is patients with various types of tumors such as melanoma, small cell lung cancer, and solid tumors that respond to immune system stimulation. Currently, the company is financed by renowned capital investors such as F-Prime Capital, HBM Healthcare Investments, and Sofinnova Investments. The company offers promising perspectives in cancer research and has the potential to deliver further advancements in the field of immuno-oncology with new products. These developments can help make cancer therapy more effective and safer, ultimately moving towards the goal of fighting cancer. Checkmate Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Checkmate Pharmaceuticals's Equity

Checkmate Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Checkmate Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Checkmate Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Checkmate Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Checkmate Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Checkmate Pharmaceuticals stock

What is the equity of Checkmate Pharmaceuticals this year?

Checkmate Pharmaceuticals has equity of 69.46 M USD this year.

What was the equity of Checkmate Pharmaceuticals compared to the previous year?

The equity of Checkmate Pharmaceuticals has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of Checkmate Pharmaceuticals?

A high equity is advantageous for investors of Checkmate Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Checkmate Pharmaceuticals?

A low equity can be a risk for investors of Checkmate Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Checkmate Pharmaceuticals affect the company?

An increase in equity of Checkmate Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Checkmate Pharmaceuticals affect the company?

A reduction in equity of Checkmate Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Checkmate Pharmaceuticals?

Some factors that can affect the equity of Checkmate Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Checkmate Pharmaceuticals so important for investors?

The equity of Checkmate Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Checkmate Pharmaceuticals take to change the equity?

To change equity, Checkmate Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Checkmate Pharmaceuticals pay?

Over the past 12 months, Checkmate Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Checkmate Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Checkmate Pharmaceuticals?

The current dividend yield of Checkmate Pharmaceuticals is .

When does Checkmate Pharmaceuticals pay dividends?

Checkmate Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Checkmate Pharmaceuticals?

Checkmate Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Checkmate Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Checkmate Pharmaceuticals located?

Checkmate Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Checkmate Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Checkmate Pharmaceuticals from 9/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/8/2024.

When did Checkmate Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/8/2024.

What was the dividend of Checkmate Pharmaceuticals in the year 2023?

In the year 2023, Checkmate Pharmaceuticals distributed 0 USD as dividends.

In which currency does Checkmate Pharmaceuticals pay out the dividend?

The dividends of Checkmate Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Checkmate Pharmaceuticals

Our stock analysis for Checkmate Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Checkmate Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.